Complete Guide to Wegovy BMI Eligibility & UK Purchase
Understanding Wegovy BMI Requirements for Online Purchase
The MHRA has approved Wegovy for weight management in adults with specific BMI thresholds that determine eligibility. Adults require a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with at least one weight-related comorbidity such as type 2 diabetes, high blood pressure, or sleep apnoea. These Wegovy BMI requirements ensure the prescription-only medicine is prescribed to patients who will benefit most from semaglutide treatment. Our online clinical assessment at EverydayMeds evaluates your BMI alongside your medical history to confirm eligibility before any prescription is issued.
For adolescents aged 12 years and older, Wegovy BMI requirements specify a body weight above 60kg with a BMI corresponding to obesity in adults. This careful assessment process protects patient safety while ensuring access to effective weight management treatment. Our GPhC-registered pharmacy (#9012878) maintains strict adherence to these licensing requirements, with experienced prescribers reviewing every application. The online assessment takes just 3 minutes and immediately calculates your BMI using your height and weight measurements.
Wegovy Pricing Structure and Bundle Options
EverydayMeds offers competitive Wegovy pricing starting from £79.99 for the 0.25mg starter dose, with our Getting Started bundles providing convenient multi-pen options. The Intro Duo bundle (0.25mg & 0.5mg) costs £169.99, covering your first 8 weeks of treatment with both initial dose escalation pens. New customers receive discount code FIRST40 at checkout, while returning customers use code DOSE25 for continued savings. Our Ultimate Stability Trio provides three months of maintenance supply at 2.4mg for £649.99, ensuring uninterrupted treatment without repeated ordering.
Individual pen pricing reflects the dose escalation schedule required for Wegovy BMI requirements compliance. The 0.5mg dose costs £94.99, progressing to £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Bundle options like our Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99 provide seamless progression through weeks 5-16 of treatment. All prices include prescriber consultation, clinical assessment review, and temperature-controlled next-day delivery of genuine Novo Nordisk products.
Clinical Evidence Supporting Wegovy BMI Eligibility Criteria
The STEP clinical trial programme established the evidence base for current Wegovy BMI requirements and licensing decisions. In STEP 1, patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 3 demonstrated that intensive behavioural therapy combined with Wegovy may support approximately clinically studied weight loss in eligible patients.
Long-term sustainability data from STEP 5 showed approximately clinically studied weight loss maintained at 2 years, while the SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events. These robust clinical results support the MHRA's Wegovy BMI requirements, ensuring treatment reaches patients most likely to achieve clinically meaningful outcomes. NICE guideline TA875 recommends Wegovy with specialist weight management support for patients meeting these specific BMI criteria.
How Wegovy Works for Patients Meeting BMI Requirements
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of natural fullness hormones in your body. The medication works on appetite centres in the brain, potentially reducing hunger signals and promoting earlier satiety after smaller meals. This mechanism helps patients meeting Wegovy BMI requirements achieve sustainable weight management by addressing the biological drivers of overeating. Semaglutide may also slow gastric emptying, prolonging feelings of fullness between meals. The once-weekly injection provides consistent appetite regulation throughout the 7-day dosing period, supporting adherence to reduced-calorie dietary plans. Clinical studies suggest Wegovy may reduce food cravings, particularly for high-calorie, palatable foods that contribute to weight gain in eligible patients.
Streamlined Online Ordering Process
Our online ordering system efficiently determines Wegovy BMI requirements compliance through a comprehensive 3-minute clinical assessment. The questionnaire captures your height, weight, medical history, current medications, and weight-related health conditions to calculate BMI and assess eligibility. Following submission, our prescribers review your application within 3 working days (or 24 hours with express service) to confirm you meet licensing criteria. Once approved, your genuine Novo Nordisk Wegovy pens are dispatched via temperature-controlled next-day delivery to maintain medication integrity. Our GPhC-registered pharmacy maintains cold-chain protocols throughout the supply process, ensuring your prescription-only medicine arrives in optimal condition. The entire process from assessment to delivery typically completes within 4 working days for standard orders.
Proper Storage and Dose Escalation Requirements
Wegovy FlexTouch pens require refrigerated storage at 2-8°C before first use, though they remain stable at room temperature below 30°C for up to 6 weeks once removed from the fridge. This storage flexibility makes Wegovy convenient for travel compared to other weight management injections with shorter room temperature stability. The mandatory dose escalation schedule begins at 0.25mg for weeks 1-4, progressing through 0.5mg, 1mg, and 1.7mg doses before reaching the 2.4mg maintenance level. Each FlexTouch pen contains 4 weekly doses, with clear dose selection and injection mechanisms. Patients cannot skip dose escalation steps, as this graduated approach minimises gastrointestinal side effects while optimising treatment tolerance. Your prescriber will provide detailed injection technique guidance and dose progression instructions with your first order.
BMI Assessment Accuracy for Online Wegovy Purchases
Accurate BMI calculation forms the cornerstone of Wegovy BMI requirements assessment, requiring precise height and weight measurements for reliable results. Our online system uses metric calculations (kg/m²) as standard, though imperial measurements are automatically converted to ensure accuracy. Patients should weigh themselves without shoes or heavy clothing, preferably in the morning for consistent results across multiple assessments. Medical-grade scales provide the most reliable weight measurements, as bathroom scales may vary by 1-2kg affecting BMI calculations near threshold values.
For patients with BMI between 27-30 kg/m², documenting weight-related comorbidities becomes essential for Wegovy eligibility assessment. Conditions such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea qualify as relevant comorbidities under MHRA licensing terms. Our clinical assessment captures detailed medical history to identify these qualifying conditions, ensuring patients receive appropriate access to treatment. Prescribers may request additional documentation for borderline cases to confirm Wegovy BMI requirements compliance.
Secure Your Wegovy Treatment Today
Begin your weight management journey by completing our confidential online assessment to verify Wegovy BMI requirements eligibility. New customers can apply discount code FIRST40 at checkout, while returning customers use DOSE25 for continued savings on genuine Novo Nordisk products. Our experienced prescribers ensure safe, appropriate access to this prescription-only medicine for qualifying patients. Start with our 0.25mg dose at £79.99, or choose bundle options for seamless dose progression through your first months of treatment. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and secure next-day delivery of your Wegovy prescription. With GPhC registration #9012878, EverydayMeds provides trusted access to licensed weight management solutions across the UK.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
